Topcon (7732) Q3 2025 earnings summary

Executive summary

• FY24 full-year outlook revised downward due to a sharper-than-expected downturn in the Positioning Business, but medium- to long-term profit growth prospects remain positive with ongoing structural reforms.

• Net sales for Q3 FY2024 were ¥153.5B, down 2% year-over-year; operating income: ¥0.8B, down 88%; net income: -¥2.9B.

• Eye Care Business maintains its full-year outlook, expecting record-high sales and operating income, driven by strong performance in the Screening Business and expansion into shared care.

• Ordinary loss of ¥2.1B, reversing from a profit of ¥4.6B in Q3 FY2023.

• Comprehensive income was negative ¥0.9B, down from ¥7.7B in Q3 FY2023.

Financial highlights

• Consolidated Q3 YTD net sales: ¥153.5B, down 2% year-over-year; operating income: ¥0.8B, down 88% year-over-year; net income: -¥2.9B.

• Gross profit for Q3 FY2024 was ¥80.9B, down from ¥83.2B year-over-year; gross profit ratio declined to 52.7%.

• Extraordinary losses included impairment and litigation costs, totaling ¥4.8B.

• Basic earnings per share was negative ¥27.18, compared to ¥3.35 in Q3 FY2023.

• Selling, general and administrative expenses increased to ¥80.1B from ¥76.7B.

Outlook and guidance

• FY24 consolidated net sales forecast revised to ¥211.0B (down 2.5% year-over-year); operating income forecast at ¥7.0B (down 38%).

• Ordinary profit expected to decline 60.5% to ¥3.5B; net profit forecast is zero.

• Positioning Business outlook: net sales ¥128.0B, operating income ¥5.0B, reflecting a challenging environment and accelerated structural reforms.

• Eye Care Business outlook unchanged: net sales ¥82.0B, operating income ¥7.5B, both record highs expected.

• Planned dividend maintained at ¥42 per share.